BNT162b2 mRNA COVID-19 vaccine three-dose safety and risk of COVID-19 in patients with myasthenia gravis during the alpha, delta, and omicron wavesArticle Published on 2022-12-012022-11-16 Journal: Journal of Neurology [Category] COVID19(2023년), SARS, 변종, [키워드] Administered Affect Alpha BNT162b2 mRNA BNT162b2 mRNA vaccine contribute COVID-19 COVID-19 mortality COVID-19 vaccine develop disease General population Mild morbidity and mortality Myasthenia myasthenia gravis outcome Patient patients raise reduced risk Respiratory failure risk risk of COVID-19 Safety SARS-CoV-2 SARS-CoV-2 variants severe COVID-19 severe disease significantly higher vaccination Vaccine vaccine dose [DOI] 10.1007/s00415-022-11303-8 PMC 바로가기
Epidemiological analysis of the first 1000 cases of SARS-CoV-2 lineage BA.1 (B.1.1.529, Omicron) compared with co-circulating Delta in Wales, UKArticle Published on 2022-11-012022-11-16 Journal: Influenza and Other Respiratory Viruses [Category] COVID19(2023년), SARS, 변종, [키워드] acute respiratory syndrome Analysis Anosmia B.1.1.529 calculated collected community transmission Contact tracing coronavirus COVID-19 Delta delta variant demographic factor Genomics hospitalisation hospitalised identify include individual less Lineage lower risk measure omicron outcome Prevent proportion Public reduced risk reduction reported risk ratio SARS-CoV-2 SARS-CoV-2 lineage Surveillance Symptom Testing Travel United Kingdom vaccination variant Wales. [DOI] 10.1111/irv.13021 PMC 바로가기
Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: A nested case-control within the SIREN studyArticle Published on 2022-11-012022-11-15 Journal: The Journal of Infection [Category] SARS, 진단, 치료기술, [키워드] age analysed anti-S anti-SARS-CoV-2 antibody association Case-control case-control study controls correlated fixed Gender identify Immunity Increasing infected individual Infection Linear regression Live virus logistic regression models Neutralising Antibodies no difference nucleocapsid occurred performed pre-vaccination protective effect pseudovirus reduced risk Reinfection required Result SARS-CoV-2 SARS-CoV-2 serology serological serology serum sample significantly lower SIREN study tested titre titres vaccination Wuhan [DOI] 10.1016/j.jinf.2022.09.004 PMC 바로가기
Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and WalesArticle Published on 2022-10-152022-11-16 Journal: Lancet (London, England) [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI adjusted age analyses Analysis aRR association B.1.1.529 benefit BNT162b2 booster booster dose Booster vaccine calculated ChAdOx1 nCoV-19 Chronic kidney disease Committee Comorbidities Comorbidity conducted core covariates COVID-19 COVID-19 hospitalisation COVID-19 infection COVID-19 therapeutics COVID-19 vaccination current death dominant Edinburgh England event group Health health condition high risk hospitalisation identify immunisation Immunosuppressant increased risk individual initial Innovation Ireland male Medical Research Council meta-analyses Moderna mortality data mRNA-1273 Multimorbidity National of BNT162b2 offer older adult outcome outcomes Oxford-AstraZeneca per 1000 person-year per 1000 person-years Pfizer-BioNTech Poisson regression model primary care prospective cohort prospective cohort study rate ratio receiving reduced reduced risk remained risk risk factor RT-PCR testing SARS-COV-2 infection Scottish severe COVID-19 Sex those with comorbidity university vaccination Vaccine vaccine dose vaccine group variant [DOI] 10.1016/S0140-6736(22)01656-7 PMC 바로가기
Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational studyArticle Published on 2022-10-082022-11-15 Journal: Lancet (London, England) [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] Abstract Admission age ambulatory patient Analysis Antiviral antiviral drug authority B.1.1.529 Case-control Charlson Comorbidity Index China Chinese clinical effectiveness Cohort Community Control COVID-19 outpatient Cox regression death Diagnosis diagnosis of SARS-CoV-2 Disease progression dominant Effectiveness glomerular filtration rate hazard Hong Kong hospitalisation HRs identify in both group In-hospital In-hospital death Infection intensive care Invasive mechanical ventilation less Logistic regression lower risk material median molnupiravir Mortality Nirmatrelvir non-hospitalised Odds ratio Older older patients outcome Outpatient Patient patients with COVID-19 primary analysis reduced risk Region Registered retrospective cohort risk Ritonavir SARS-CoV-2 SARS-COV-2 infection sensitivity analysis Sex supported the SARS-CoV-2 translation used data vaccination variant [DOI] 10.1016/S0140-6736(22)01586-0 PMC 바로가기
SARS-CoV-2 Omicron: Light at the End of the Long Pandemic Tunnel or Another False Dawn for Immunodeficient Patients?Article Published on 2022-09-012022-11-15 Journal: The journal of allergy and clinical immunology. In [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] addition Antibody evasion appear caused COVID-19 COVID-19 infection COVID-19 vaccine CVID dawn deaths End Fatality rate form group healthy individuals Hospitalization immunodeficiency immunodeficient patients implication individual innate immune less LIGHT Long lung damage morbidity offer offered omicron outcomes pandemic Patient Perspective physical Psychiatric reduced risk respond risk SARS-CoV-2 SARS-CoV-2 variants severe disease survivor T-cell the SARS-CoV-2 those with comorbidity Tunnel variant [DOI] 10.1016/j.jaip.2022.06.011 PMC 바로가기
Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic reviewResearch article Published on 2022-08-272022-10-05 Journal: EClinicalMedicine [Category] 바이오마커, [키워드] acute SARS-CoV-2 infection article association assumption case-controls changes in CINAHL Cohort studies collected COVID-19 COVID-19 vaccination decrease dose effective Evidence finding funding Impact individuals investigated long-COVID Long-COVID symptoms Methodological quality peer-reviewed study post-COVID syndrome Prevalence reduce reduced risk reported risk SARS-CoV-2 SARS-COV-2 infection searched subsequent supported Survivors Symptom systematic review the Newcastle-Ottawa Scale vaccination Vaccine vaccine administration Web of Science worsening [DOI] 10.1016/j.eclinm.2022.101624 [Article Type] Research article
SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohortVirus Watch 코호트의 SARS-CoV-2 항체 및 획기적인 감염Article Published on 2022-08-182022-09-12 Journal: Nature Communications [Category] SARS, 진단, [키워드] 95% confidence interval anti-S anti-S antibody antibody BNT162b2 booster vaccination Breakthrough infection ChAdOx1 clinically Cohort Course Delta Effectiveness Efficacy Evidence geometric hazard higher risk Increasing individual Infection nine Older protective effect provide Ratio reduced risk risk risk of infection SARS-CoV-2 antibody SARS-COV-2 infection SARS-CoV-2 vaccine second dose Support the timing total effect Vaccine [DOI] 10.1038/s41467-022-32265-5 PMC 바로가기 [Article Type] Article
Association of COVID-19 Vaccination During Pregnancy With Incidence of SARS-CoV-2 Infection in Infants유아의 SARS-CoV-2 감염 발생률과 임신 중 COVID-19 예방 접종의 연관성Article Published on 2022-08-012022-09-11 Journal: JAMA Internal Medicine [Category] Fulltext, SARS, 변종, [키워드] 95% CI adjusted hazard ratio age Birth Chain Reaction cohort study country COVID-19 COVID-19 pandemic COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines Cox proportional hazard regression Delta delta variant determine dose during pregnancy Follow-up hazard ratio incidence rate Infant Infants life lower risk Maternal maternal age Messenger RNA mother Norway omicron Omicron variant outcome parity polymerase chain polymerase chain reaction population-based cohort positive Positive test Pregnancy pregnant women provide receive reduce reduced risk residence risk SARS-CoV-2 severe COVID-19 stratified suggested test result vaccination Vaccination Status variant variants was used women [DOI] 10.1001/jamainternmed.2022.2442 PMC 바로가기 [Article Type] Article
Antiviral drug treatment for nonsevere COVID-19: a systematic review and network meta-analysis중증이 아닌 COVID-19에 대한 항바이러스제 치료: 체계적인 검토 및 네트워크 메타 분석Meta-Analysis Published on 2022-07-252022-09-11 Journal: CMAJ : Canadian Medical Association journal = jour [Category] COVID19(2023년), meta-analysis, SARS, 변종, 치료제, [키워드] 95% CI 95% confidence interval Admission Adult patients antiviral drug antiviral drugs antiviral treatments approach assessment certainty certainty of evidence conducted COVID-19 database death development drug effective Effectiveness Evidence Hospital admission Hospital admissions moderate molnupiravir MOST Network meta-analysis Nirmatrelvir no effect omicron Omicron variant Patient patients patients with COVID-19 performed Placebo randomized trial randomized trials reduce reduced risk reducing Remdesivir risk Risk of bias risk of death Ritonavir searched standard care systematic review tested Treatment Trial trials variants [DOI] 10.1503/cmaj.220471 PMC 바로가기 [Article Type] Meta-Analysis